1. Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia
- Author
-
Fabio De Martin, Alessandro Moro, Elisa Michelesio, Francesca Valent, Daniela Macor, Maria Rosalia Da Riol, Laura Deroma, Paolo Martina, Bruno Bembi, and Giovanni Ciana
- Subjects
Adult ,Male ,administrative health data ,data linkage ,disease registry ,Italy ,rare diseases ,medicine.medical_specialty ,Common disease ,Efficiency, Organizational ,03 medical and health sciences ,Health services ,0302 clinical medicine ,Clinical Protocols ,Ambulatory care ,Epidemiology ,Humans ,Medicine ,Public Health Surveillance ,Registries ,030212 general & internal medicine ,Medical prescription ,Aged ,business.industry ,030503 health policy & services ,Health Policy ,Public Health, Environmental and Occupational Health ,Health Services ,Middle Aged ,Patient Acceptance of Health Care ,Hospitalization ,Friuli venezia giulia ,Socioeconomic Factors ,Emergency medicine ,Health Resources ,Female ,Health Expenditures ,0305 other medical science ,business ,Pediatric population ,Rare disease - Abstract
Background The lack of epidemiological and clinical data is a major obstacle in health service planning for rare diseases. Patient registries are examples of real-world data that may fill the information gap. Objective We describe the Rare Disease Registry of the Friuli Venezia Giulia region of Italy and its potential for research and health planning. Methods The Rare Disease Registry data were linked with information on mortality, hospital discharges, ambulatory care, and drug prescriptions contained in administrative databases. All information is anonymous, and data linkage was based on a stochastic key univocal for each patient. Average annual costs owing to hospitalizations, outpatient care, and medications were estimated. Results Implementation of the Registry started in 2010, and 4250 participants were registered up to 2017. A total of 2696 patients were living in the region as of January 1, 2017. The overall raw prevalence of rare diseases was 22 per 10,000 inhabitants, with higher prevalence in the pediatric population. The most common disease groups were congenital malformations, chromosomal and genetic syndromes, and circulatory and nervous diseases. In 2017, 30 patients died, 648 were hospitalized, and 2355 received some type of ambulatory care. The total annual estimated cost was approximately €6.5 million, with great variability in the average patient cost across diseases. Conclusions The possibility of following the detailed real-world care experience of patients with each specific rare disease and assessing the costs related to each step in their care path represents a unique opportunity to identify inefficiencies, optimize care, and reduce waste of resources.
- Published
- 2019
- Full Text
- View/download PDF